Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Anti-PD-1 Antibody Camrelizumab in the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation

NCT04564313 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT04564313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04564313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Anti-PD-1 Antibody Camrelizumab in the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplantation
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 1
Overall status
Unknown status
Start date
September 21, 2020
Completion date
July 31, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liver transplantation